The stock is trading at $173.27 just a bit higher than the 50 day moving average which is $162.22 and which is just a bit higher than the 200 day moving average of $162.64. The 50 day moving average went up $11.05 or +6.81% and the 200 day average was up $10.63. Amgen Inc. shares had a trading volume of 1,957K in the last trading session. Volume was down 39.49% under the stocks average daily volume.
Traders are a little more bearish on Amgen Inc. as shown by the rise in short interest. The company saw a rise in short interest of 11.16% as of the latest report on May 31, 2017. Short interest increased 904,869 over that timeframe. The short-interest ratio increased to 2.6 and the percentage of shorted shares is 0.01% as of May 31.
There has been some selling insider activity on Amgen Inc. (NASDAQ:AMGN) recently. David Baltimore, Director reported the sale of 3,700 shares of (AMGN). The shares were purchased at an average price of $153.93. The Director now owns $4,796,305 of the stock according to the SEC filing. Cynthia M. Patton, SVP & CCO disclosed the sale of 2,922 shares. The shares were sold on May 24th for an average price of $154.40. Patton now owns $3,287,485 of the stock per the Form 4 SEC filing.
VP, Finance and CAO Annette Louise Such disclosed the sale of 3,000 shares of AMGN stock. The shares were purchased at an average price of $174.59. The VP, Finance and CAO now owns $1,254,080 of the stock per the Form 4 SEC filing.
These firms have also modified their investment in AMGN. As of quarter end Sowell Financial Services LLC had bought a total of 733 shares growing its position 21.2%. The value of the total investment in Amgen Inc. increased from $593,000 to $647,000 a change of 9.1% quarter over quarter. Piedmont Investment Advisors LLC cut its investment by shedding 43,325 shares a decrease of 21.3% from 12/31/2016 to 03/31/2017. Piedmont Investment Advisors LLC now controls 160,257 shares with a value of $26,293,000. The total value of its holdings decreased 11.7%.
As of the end of the quarter Ballentine Partners, LLC had disposed of 2,281 shares trimming its stake by 99.8%. The value of the investment in Amgen Inc. went from $335,000 to $1,000 decreasing 99.7% quarter to quarter. Shamrock Asset Management LLC downsized its stake by selling 240 shares a decrease of 6.6% as of 03/31/2017. Shamrock Asset Management LLC controls 3,410 shares worth $559,000. The value of the position overall is up by 4.7%.
On July 11 Morgan Stanley kept the stock rating at “Overweight” and moved down the price target to $189.00 from $198.00. Equity analyst Oppenheimer issued its first research report on the stock giving it an initial rating of “Outperform”.
Mizuho initiated coverage by announcing an initial rating of “Buy”. September 28 investment analysts at Citigroup maintained a company rating of “Neutral” but moved down the price target from $198.00 to $172.00.
On August 26, 2016 Gabelli & Co. began coverage of the stock with a rating of “Hold”. On June 29 analysts at Bernstein starting coverage on AMGN setting a rating of “Market Perform”.
In the market the company is trading down since yesterday’s close of $173.32. Additionally the company announced a dividend for shareholders paid on Thursday June 8th, 2017. The dividend payment was $1.150 per share for the quarter which is $4.60 annualized. This dividend amount represented a yeild of $2.67. The ex-dividend date was set for Monday the 15th of May 2017.
The company’s P/E ratio is 16.46 and the market cap is 127.42B. In the last earnings report the EPS was $10.53 and is estimated to be $12.45 for the current year with 735,399,000 shares presently outstanding. Next quarter’s EPS is forecasted to be $3.12 and the next full year EPS is anticipated to be $12.76.
Amgen Inc., launched on October 31, 1986, is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company operates in the human therapeutics segment. The Business’s marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine). The Company focuses its research and development on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience..